{"id":"NCT01189461","sponsor":"Pfizer","briefTitle":"Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema","officialTitle":"An Open Label, One Year, Non-Comparative Study To Evaluate The Safety And Tolerability Of Intravitreous Pegaptanib Sodium In Patients With Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2010-08-26","resultsPosted":"2013-09-06","lastUpdate":"2013-09-06"},"enrollment":46,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anti- VGF Inhibitor","Diabetic Macular Edema","Diabetic Retinopathy"],"interventions":[{"type":"DRUG","name":"pegaptanib sodium","otherNames":[]}],"arms":[{"label":"pegaptanib sodium arm","type":"EXPERIMENTAL"}],"summary":"This study will asses sthe safety of pegaptanib sodium in patients with diabetic macular edema. The hypothesis is that pegaptanib is safe and efficacious in patients with diabetic macular edema.","primaryOutcome":{"measure":"Incidence of Ocular and Non-Ocular Adverse Events (AEs)","timeFrame":"Baseline up to 30 days after last dose","effectByArm":[{"arm":"Macugen","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":12,"countries":["Finland","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["25187694"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5751036&StudyName=Study%20To%20Evaluate%20Safety%20And%20Tolerability%20Of%20Pegaptanib%20Sodium%20In%20Patients%20With%20Diabetic%20Macular%20Edema"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":46},"commonTop":["Macular oedema","Visual acuity reduced","Anaemia","Cataract","Conjunctival haemorrhage"]}}